Stockscreener 앱 받기
54.04
0.24%
0.13
시간 외 거래:
54.23
0.19
+0.35%
전일 마감가:
$53.91
열려 있는:
$53.95
하루 거래량:
1.12M
Relative Volume:
0.54
시가총액:
$4.32B
수익:
-
순이익/손실:
$-269.44M
주가수익비율:
-14.41
EPS:
-3.75
순현금흐름:
$-262.63M
1주 성능:
-0.30%
1개월 성능:
+17.48%
6개월 성능:
+26.29%
1년 성능:
+54.98%
1일 변동 폭
$53.93
$54.10
1주일 범위
$53.90
$54.20
52주 변동 폭
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
명칭
Akero Therapeutics Inc
전화
650-487-6488
주소
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.04 | 4.32B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-08-04 | 개시 | TD Cowen | Buy |
| 2025-01-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-18 | 개시 | Citigroup | Buy |
| 2024-04-22 | 재개 | BofA Securities | Neutral |
| 2023-09-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 개시 | UBS | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 개시 | Guggenheim | Buy |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-07-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-02 | 개시 | H.C. Wainwright | Buy |
| 2020-02-10 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Evercore ISI | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
| 2019-07-15 | 개시 | Jefferies | Buy |
| 2019-07-15 | 개시 | ROTH Capital | Buy |
모두보기
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
Akero Therapeutics, Inc. SEC 10-Q Report - TradingView
Novo Nordisk, Akero Therapeutics filed HSR paperwork on Nov. 5 - MLex
Halper Sadeh LLC Encourages JAMF, CADE, AKRO, GES Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Is Akero Therapeutics Inc. stock attractive for growth ETFsTrade Ideas & Weekly High Momentum Picks - newser.com
Will Akero Therapeutics Inc. (0K4) stock rise with strong economy2025 Dividend Review & Long-Term Growth Portfolio Plans - newser.com
Is Akero Therapeutics Inc. stock supported by innovation pipeline2025 Market Sentiment & AI Driven Stock Movement Reports - newser.com
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and Harmony Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting®? 2025 - MarketScreener
Akero Therapeutics presents new phase 2b trial data on efruxifermin at AASLD liver meeting 2025 - MarketScreener
Akero reports positive efruxifermin data for MASH at liver conference - Investing.com India
Akero (NASDAQ: AKRO) presents 96‑week data: CSPH risk improved, AI confirms fibrosis - Stock Titan
Heatmap analysis for Akero Therapeutics Inc. and competitors2025 Pullback Review & Verified Momentum Watchlists - newser.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (NasdaqAKRO), CoreCard Corporation (NYSE - GlobeNewswire Inc.
Can Akero Therapeutics Inc. (0K4) stock beat analyst consensusJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Can volume confirm reversal in Akero Therapeutics Inc.2025 Top Gainers & High Win Rate Trade Tips - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunityJuly 2025 EndofMonth & Trade Opportunity Analysis Reports - newser.com
Can Akero Therapeutics Inc. stock hit record highs againQuarterly Trade Review & Low Risk Growth Stock Ideas - fcp.pa.gov.br
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsJuly 2025 Levels & Verified Chart Pattern Signals - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
How rising interest rates impact Akero Therapeutics Inc. stock2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Chart based analysis of Akero Therapeutics Inc. trendsJuly 2025 Drop Watch & Low Drawdown Trading Techniques - newser.com
How high can Akero Therapeutics Inc. stock goTrade Ideas & Weekly High Momentum Picks - newser.com
Will Akero Therapeutics Inc. stock sustain high P E ratios2025 Short Interest & Free Long-Term Investment Growth Plans - fcp.pa.gov.br
Will Akero Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
Using RSI to spot recovery in Akero Therapeutics Inc.July 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Will Akero Therapeutics Inc. outperform the market2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Lelezard
Is Akero Therapeutics Inc. (0K4) stock included in top ETFs2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Why (AKRO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Why Akero Therapeutics Inc. stock is recommended by analystsQuarterly Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
Is Akero Therapeutics Inc. stock a buy before product launchesWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Akero Therapeutics Inc (AKRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.44%
0.70%
자본화:
|
볼륨(24시간):